Medicus IT Announces Supplier Agreement with EyeProGPO to Enhance Services Reach

Medicus IT (“Medicus” or “the Company”), the leading healthcare-focused IT managed services provider, today announced that it has signed a strategic supplier agreement with EyeProGPO to significantly enhance its services reach across the nation within the ophthalmology segment. This collaboration aligns the shared mission of both organizations to improve patient outcomes through innovative, scalable, and secure IT solutions.

Through this partnership, Medicus IT, already a leader in the ophthalmology space and renowned for aiding ophthalmology practices nationwide with cutting-edge technology tailored to the needs of providers, patients, and staff, will expand its reach to over 1100 members of EyeProGPO. This expansion further solidifies Medicus’ position as the premier IT solutions provider dedicated to healthcare and the unique complexities of maintaining secure IT environments.

EyeProGPO members will now benefit from exclusive access to Medicus’ suite of comprehensive services and competitive pricing, enhancing their operational efficiency and patient care quality. Additionally, members will gain insights into leveraging IT for optimized practice operations, leading to cost savings and improved patient satisfaction.

“This partnership marks a significant milestone for Medicus and its membership in specialty-focused GPOs,” said Daniel Livschutz, Senior Vice President of Business Development, Medicus IT. “By leveraging the extensive network of EyeProGPO, we are positioned as the healthcare IT solutions partner of choice within their membership group. This allows us to reach over 1,100 eye care facilities with technology solutions designed to foster growth and improve patient outcomes. We’re also excited to provide an opportunity for our customers to learn more about the savings and efficiency EyeProGPO brings to their healthcare organizations. This partnership allows both organizations to continue winning together.”

Medicus IT is such a great fit for EyeProGPO. We are steadfast in our commitment to offer our members unrivaled value and savings. Through this new partnership, we’re ensuring that our members have access to the best IT services and support on the market. We believe our combined strengths will increase value for healthcare providers across the nation,” says Phil Meyer, COO of EyeProGPO.

This agreement underscores Medicus’ unwavering commitment to fostering alliances that drive innovation and growth in the healthcare industry. As we continue to expand our capabilities, we remain dedicated to enabling healthcare providers to focus on their patients by ensuring their IT infrastructure is secure, efficient, and scalable.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.